FASN and hepatocellular carcinoma: Mechanisms underlying HCC inhibition by FASN inhibitors merit further studies to distinguish between indirect effects by reducing the metabolic, inflammatory and fibrogenic drivers of tumorigenesis and direct effects on early tumor cells.